FDA Approves FARXIGA — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's FARXIGA for Diabetes Treatment AstraZeneca Pharmaceuticals LP received FDA approval for FARXIGA (dapagliflozin), an oral diabetes medication that expands the company's endocrinology portfolio and positions it to compete in the growing SGLT2 inhibitor market. The approval opens significant revenue opportunities for AstraZeneca in a therapeutic category projected to see substantial growth as diabetes prevalence increases globally.